Weight-Loss Medicines: The Questions They Raise

Not how to take them — what the trials show, what happens to muscle, and what the evidence says about stopping.

What this is

GLP-1-based medicines changed obesity medicine, and the evidence behind them is unusually strong for this field: large randomised placebo-controlled trials with clinically meaningful weight and metabolic outcomes, reviewed by regulators. Our peptides register covers what they are and how they differ from unregulated "research peptides".

This page covers the research questions they raise: what is being lost along with the fat, what side-effects look like in the trials, and what happens to weight after stopping. If you are on one of these medicines and the question is what to actually eat, that is a different and more useful page — our eating-on-a-GLP-1 guides cover food, protein, digestion and the medicines compared.

What the evidence says

  • Substantial average weight loss in randomised trials

    Gold· human data

    The STEP programme for semaglutide and SURMOUNT for tirzepatide reported large placebo-controlled reductions in body weight over roughly a year, in thousands of participants.

  • A meaningful share of the loss is lean mass

    Gold· human data

    Body-composition substudies and reviews of GLP-1-based therapies consistently find lean tissue makes up a substantial fraction of total weight lost — broadly in line with what any large energy deficit does, which is exactly why the resistance-training and protein questions matter here.

  • Gastrointestinal side-effects are common

    Gold· human data

    Nausea, vomiting, constipation and diarrhoea are the most frequently reported adverse effects in the trials, and the most common reason for stopping.

  • Weight is regained after stopping

    Gold· human data

    Withdrawal studies show most of the lost weight returns over the following year. These are treatments for an ongoing condition rather than a course with an endpoint — a framing the marketing rarely leads with.

  • They are a shortcut that makes training and diet irrelevant

    Not supported

    The lean-mass and regain findings point the other way: resistance training and adequate protein matter more during pharmacological weight loss, not less.

What this means in practice

  • The two things within your control that address the lean-mass finding are resistance training and hitting a protein target. The protein-and-muscle guide in our GLP-1 nutrition cluster works through the food side; our protein calculator sets the number.
  • Appetite suppression makes protein and micronutrients easy to miss. That's an eating problem with an eating answer — see what to eat on GLP-1 medication.
  • Track something other than weight — waist measurement, strength numbers, how clothes fit. Scale weight alone can't tell you what you lost.
  • Discuss the exit question with your prescriber at the start, not at the end.
  • Report persistent vomiting, severe abdominal pain or signs of dehydration to a clinician promptly rather than pushing through.

When to see a doctor

  • Severe or persistent abdominal pain, which needs urgent assessment.
  • Persistent vomiting or inability to keep fluids down.
  • Rapid weight loss with weakness, dizziness or fainting.
  • Any use of a product obtained outside a regulated pharmacy — stop and speak to a clinician.

The honest summary

The trial evidence for weight loss is strong and the regain data are equally clear. Both point the same way for anyone reading a fitness site: the medicine changes appetite, and what protects your muscle and your result afterwards is still lifting and protein.

Work it out

See also

Frequently asked questions

Do weight-loss injections cause muscle loss?
A substantial share of the weight lost is lean tissue, in line with other large energy deficits. That's an argument for resistance training and adequate protein during treatment, and it's why body-composition substudies get so much attention.
What happens if you stop?
Withdrawal studies show most weight returns over the following year. They're best understood as long-term treatment for an ongoing condition rather than a fixed course.
Are they safe?
They're licensed medicines with a substantial trial safety base and real side-effects, mostly gastrointestinal, plus specific contraindications. Whether they're safe for you is a clinical question for a doctor with your history — not something a website can answer.
What about grey-market or 'research' versions?
They carry the same purity, dosing and contamination risks as any unregulated compound. The regulatory process is the thing that makes a product what its label claims; unlicensed vials skip it.

Sources

Written and reviewed by Mathew Beale, MSc Biotechnology, University of Reading.

Last reviewed: